108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
淋巴细胞计数在预测中国人群甲状腺乳头状癌风险中的临床价值：一项病例对照研究
Authors Qiu XP, Xie RY, Chen Y, Tu M, Wang T
Received 13 March 2025
Accepted for publication 1 September 2025
Published 19 September 2025 Volume 2025:18 Pages 12971—12988
DOI https://doi.org/10.2147/JIR.S528176
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Felix Marsh-Wakefield
Xiu-Ping Qiu, Ru-Ying Xie, Yang Chen, Mei Tu, Ting Wang
Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, 364000, People’s Republic of China
Correspondence: Ting Wang, Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, People’s Republic of China, Tel +86 13956044997, Tel +86 13956044997, Email 271210272@qq.com Mei Tu, Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, People’s Republic of China, Tel +86 13859596628, Email meituuui@126.com
Objective: This study aimed to evaluate the association between preoperative peripheral blood lymphocyte count and the risk of papillary thyroid carcinoma (PTC) in a Chinese population using a case-control design.
Methods: A retrospective analysis was conducted on 1832 patients who underwent thyroid surgery, including 1007 diagnosed with benign thyroid nodules and 825 with PTC. Clinical parameters, including lymphocyte count, nodule volume, thyroid function, and thyroid autoantibody levels, were assessed. Multivariate regression and stratified analyses were conducted to examine the relationship between lymphocyte count and PTC risk.
Results: The mean lymphocyte count was significantly higher in patients with PTC compared to those with benign thyroid nodules (1.20 ± 0.63 vs 1.87 ± 0.53, p < 0.001). Multivariate regression analysis indicated a dose-response relationship, with patients in the highest lymphocyte count group exhibiting an odds ratio of 15.02 (95% CI: 7.52– 30.03, p < 0.0001). Receiver operating curve analysis demonstrated good diagnostic performance (AUC = 0.8068). Stratified analyses revealed variations in risk patterns across subgroups stratified by age, sex, and nodule volume.
Conclusion: Lymphocyte count may serve as a potential predictor of PTC risk. This finding may provide new insights into early clinical risk stratification and personalized screening strategies in the management of PTC.
Keywords: biomarker, immune microenvironment, inflammatory markers, papillary thyroid carcinoma, peripheral blood lymphocyte count, risk assessment, thyroid nodules
Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, 364000, People’s Republic of China
Correspondence: Ting Wang, Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, People’s Republic of China, Tel +86 13956044997, Tel +86 13956044997, Email 271210272@qq.com Mei Tu, Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, People’s Republic of China, Tel +86 13859596628, Email meituuui@126.com
Objective: This study aimed to evaluate the association between preoperative peripheral blood lymphocyte count and the risk of papillary thyroid carcinoma (PTC) in a Chinese population using a case-control design.
Methods: A retrospective analysis was conducted on 1832 patients who underwent thyroid surgery, including 1007 diagnosed with benign thyroid nodules and 825 with PTC. Clinical parameters, including lymphocyte count, nodule volume, thyroid function, and thyroid autoantibody levels, were assessed. Multivariate regression and stratified analyses were conducted to examine the relationship between lymphocyte count and PTC risk.
Results: The mean lymphocyte count was significantly higher in patients with PTC compared to those with benign thyroid nodules (1.20 ± 0.63 vs 1.87 ± 0.53, p < 0.001). Multivariate regression analysis indicated a dose-response relationship, with patients in the highest lymphocyte count group exhibiting an odds ratio of 15.02 (95% CI: 7.52– 30.03, p < 0.0001). Receiver operating curve analysis demonstrated good diagnostic performance (AUC = 0.8068). Stratified analyses revealed variations in risk patterns across subgroups stratified by age, sex, and nodule volume.
Conclusion: Lymphocyte count may serve as a potential predictor of PTC risk. This finding may provide new insights into early clinical risk stratification and personalized screening strategies in the management of PTC.
Keywords: biomarker, immune microenvironment, inflammatory markers, papillary thyroid carcinoma, peripheral blood lymphocyte count, risk assessment, thyroid nodules